Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
The patient had a high-grade DCIS with necrosis, but a 0.9 DCSionRT score
Answer from: Radiation Oncologist at Community Practice
For now, I have been only omitting/discussing omission if both, clinical path and molecular test are concordant.
Sign In
or
Register
to read more
21306
Related Questions
Would you forgo lumpectomy cavity boost for grade 1 papillary carcinoma with associated grade 1 DCIS that has been resected with good margins?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Would you offer prone APBI with IMRT/VMAT?
How do you manage symptomatic fat necrosis following adjuvant breast radiotherapy?
How would you manage a pT2N1a invasive ductal carcinoma s/p lumpectomy and sentinel lymph node biopsy with ECE, and two mildly avid axillary lymph nodes on post-op PET/CT?
In what patients is it inappropriate to offer DCISionRT testing?
When using hypofractionated whole breast radiotherapy with a simultaneous integrated boost to the lumpectomy cavity, what IGRT strategy do you use?
What dose of reirradiation would you consider for locally recurrent breast cancer after mastectomy, excised with positive margins?
Does micropapillary subtype for a G1-2 DCIS affect your radiation treatment recommendations?
How do you treat a patient with early-stage breast cancer s/p lumpectomy and oncoplastic reconstruction with a positive margin, when re-excision is not feasible?